Abstract:

Polycystic ovary syndrome (PCOS) is a highly heterogeneous gynecological endocrine disease with clinical manifestations of ovulation disorders, menstrual disorders, hirsute, acne and even infertility. It is often accompanied by metabolic disorders such as obesity, insulin resistance (IR) and dyslipidemia. The pathogenesis of PCOS remains unclear. IR is the main pathological basis of PCOS, which is closely related to the changes of reproductive function such as abnormal level of sex hormones, abnormal follicle development and the reduced endometrial receptivity. Gut microbiome, known as the "second genome of human body", plays a variety of functions in maintaining the homeostasis of the host′s internal environment, such as preventing pathogens from invading the host, regulating absorption and metabolism of nutritional materials, and maintaining the stability of immune system and nervous system. In recent years, many studies have reported that the changes of gut microbiome composition can cause IR through endotoxemia, bile acid, chronic low-grade inflammation and other ways, thus promoting the occurrence and development of PCOS.

Key words: Polycystic ovary syndrome, Insulin resistance, Gut microbiome, Metabolism, Therapy